Background: Bone-marrow mesenchymal stem-cells (BMMSCs) efficaciously used in treatment of many immune diseases. Objectives: The aim of the current study was to investigate the therapeutic value of MSCs in treatment of EAP treated with Tacrolimus. Methodology: 25 albino-rats were divided into 5 equal groups (5 rats in each group): Group-I received normal phosphate-buffered saline (Control), Group-II: EAP model with no treatment. Group-III: EAP treated with tacrolimus, Group-IV: EAP treated with systemic MSCs and Group-V: EAP treated with combined tacrolimus and MSCs. The prostatic tissue regeneration investigated through detection of levels of TNF-α and IL-1β gene-expression, histological, fluorescent and immune-histochemical studies. Results: Combined treatment proved to decrease expression of both TNF-α and IL-1β in group-V when compared with the other EAP groups either received treatment or not (groups-II, III, and IV). Photomicrographic examination of the prostatic tissue showed a more evident regeneration in EAP groups (group-IV and V) when compared to tacrolimus group-III. Group-V showed evidence of complete regeneration of most of prostatic acini. The degree of cell apoptosis was evident by strong caspace-3 reaction in EAP untreated group, while the therapeutic effect of MSCs proved by very weak caspace-3 reaction in group-IV and V. The degree of proliferation in the acinar nuclei was evident by strong positive cell nuclear antigen (PCNA) reaction in groups-III, IV, V. No significant difference detected by histomorphometric measurement of both caspase-3 and PCNA among groups-III, IV and V. Conclusion: Our study demonstrated an adjuvant therapeutic effect of MSCs to tacrolimus in treatment of EAP.